BM was the source of stem cells in 93% (children) and 67% (adults) and TBI was not part of the regimen in 72% of children and 46% of adults. Results: In the autologous transplantation group: the 2-years probabilities (patients in CR1, children and adults) for TRM were respectively 6% and 9%, RI: 42% and 55%, LFS: 52% and 36% and OS: 59% and 38%. In the multivariate analysis, adults had a lower RI if the median age was lower than 45 years (p=0.04, RR=0.41) and if they did not receive TBI (p=0.03, RR=0.37). In the HLA-identical allogeneic transplant group: TRM were respectively 0% and 25%, RI: 33% and 26%, LFS: 67% and 49% and OS: 80% and 42% (children and adults). In the multivariate analysis, patients in CR1 had a lower RI (p=0.003, RR=0.32) with a higher LFS (p<0.0001, RR=0.26) and TRM was higher in adults (p=0.03, RR=13.6). Conclusion: These preliminary data suggest a higher survival after both autologous and HLA-identical allogeneic transplantation compared to known results with chemotherapy alone. For allogeneic transplant, survival was better in patients transplanted in CR1.
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Itraconazole prevents invasive fungal infection in neutropenic patients: evidence from a meta-analysis of 2,711 patients A. Glasmacher, A. Prentice, M. Gorschlueter, S. Engelhart, C. Hahn, B. Djulbegovic, I. Schmidt-Wolf (Bonn, D; Plymouth, UK; Tampa, USA) Background: Treatment of haematological malignancy with chemotherapy and stem cell transplantation is potentially curative but complicated by invasive fungal infection (invasive fungal infections) with a high mortality rate. Efficacy of prophylaxis against the range of fungi responsible has not yet been proven in numerous trials and meta-analyses but the flaws in these studies as well as new evidence justify this metaanalysis of the trials using itraconazole alone. Methods: Randomized, controlled studies with itraconazole for antifungal prophylaxis in neutropenic patients were identified. The primary endpoint was the incidence of proven invasive fungal infections (localised sino-nasal infections excluded). Findings: Ten studies with 2711 patients/episodes were included. Itraconazole reduced the incidence of proven invasive fungal infection (reduction 44%, P=0.002), the incidence of invasive yeast infections (59%, P=0.003) and the mortality from invasive fungal infections (44%, P=0.02) significantly. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution (57%, P=0.03) and not itraconazole capsules (P=0.2; test for heterogeneity between subtotals: P=0.02). The overall mortality was not changed. Adverse effects were rare, hypokalaemia was noted in two trials and higher rate of drug discontinuation was found in trials that compared itraconazole cyclodextrine solution to a control without cyclodextrine. The effect of prophylaxis was clearly associated with a higher bioavailable dose of itraconazole. Interpretation: Antifungal prophylaxis with itraconazole effectively prevents proven invasive fungal infections and reduces mortality from these infections in neutropenic patients with haematological malignancies. The higher doses of the oral cyclodextrine solution of itraconazole are responsible for these benefits.
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The Comparing the lipid-based formulations, Abelcet(R) and Ambisome(R), with conventional AmB, the number-needed-totreat (NNT) to prevent one death was 31; and the risk of serum creatinine doubling was significantly reduced by an estimated 58% (OR: 0.42; CI: 0.33-0.54) with an NNT of six. There was no significant risk reduction in infusion-related reactions with lipidbased formulations. This study demonstrated advantages with lipid-based formulations over conventional AmB in terms of reduced risk of mortality and renal toxicity.
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Influence of cell dose on the response to granulocyte transfusions in neutropenic patients with severe infections C. Peters, M. Minkov, S. Matthes-Martin, U. Pötschger, V. Witt, G. Mann, P. Höcker, N. Worel, J. Stary, T. Klingebiel, H. Gadner, H. Einsele (Vienna, A; Prague, CZ; Frankfurt, Tuebingen, D) Severe infections in neutropenic immunocompromised patients are still associated with high mortality despite of appropriate antibacterial and antifungal treatment. In a prospective study we evaluated the feasibility and efficacy of granulocyte transfusions (GT) in paediatric and adult patients with malignancies or haematological disorders. Indication for GT were severe bacterial or fungal infections. A total of 94 septic episodes (32 bacterial, 50 fungal, 12 unknown) in 78 patients are included in the present analysis. A total of 785 GTs (371 from prednisolone-primed volunteers and 414 from rhG-CSF-stimulated family donors) were administered. All GT were irradiated with 30 Gy and infused as soon as possible after harvesting. We evaluated the response to GT in the paediatric population (age <18years, 43 patients) compared to that in adult patients (age >18 years 35 patients). The median number of GT per septic episode was 8.5 (2-40) in the paediatric and 4 (1-65) in the adult group, respectively. Children received a median of 0.44 G ANC/kg body weight with prednisolone-elicited GT and 2.29 G ANC/kg with G-CSF elicited GT. In contrast, adults received 0.29 G ANC/kg (prednisolonelicited GT) or 0,46 G ANC/kg (G-CSF elicited GT), respectively. Paediatric patients receiving prednisolone-elicited GT achieved a median ANC increment of 0.30 G/l (range: -1.87 to +3.71) after the first LT versus 1.48 G/l (range: 0 to +18.61) in patients receiving rhG-CSF elicited GT. In contrast, no signifant difference was found in the cohort of adult pts. The probability to reach sustained ANC >0.5 G/l within 7 days of GT was 77±5% in the paediatric group versus 39±5% in the group of adult patients. Correlated to patient's body weight this variable was 90±5% for weight <30 kg, 68±8% for weight 30-60 kg, 31±4% for weight >60 kg. No significant influence was found by the time of neutropenia before GT, the underlying disease and the indication (bacterial vs fungal infection), respectively. GT were generally well tolerated in both, paediatric and adult groups. We conclude that the cell dose of GT is important for achievement of sustained ANC increment in severely neutropenic patients. Thus, the choice of the stimulation modality of the donor and the frequency of GT should include the consideration for the patient's body weight.
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Hematopoietic progenitor cell transplants in patients with previous history of invasive fungal infection S.J. Vaidya, M. Lopez-Duarte, B. Sirohi, A. Richardson, J. Treleaven, R. Powles, C.R. Pinkerton, M. Ortin, C. Richard (Sutton, UK; Santander, E) Invasive fungal infections (IFI) are a potential contraindication for haemopoietic progenitor cells transplant (HPCT). With the aim of studying the outcome of patients receiving HPCT after being treated for IFI, we conducted a retrospective study between the Royal Marsden NHS Trust (UK) and H.U. Marques de Valdecilla (Spain). 27 patients (median age 38 years, range 3-74) received a HPCT [15 autologous, 12 allogeneic (9 related and 3 unrelated)] between Aug-89 and Dec-2001, after a documented IFI. Indications for HPCT included: AML (14 CR1, 3 CR2), ALL (5 CR1, 3 CR2), undifferentiated leukaemia (1) and multiple myeloma (1). Conditioning regimens included total body irradiation (TBI) in 10 patients. The median time from diagnosis of IFI to HPCT was 131 days (range 21-807). The diagnosis of IFI was microbiologicaly proven in 21 cases (18 aspergillosis, 1 fusarium, 1 aspergillosis+fusarium) and only radiologically in 6. Pre-HPCT treatment included IV antifungals in all patients (amphotericin B in 19, liposomal amphotericin in 7 and voricanazole in 1) plus surgical excision in 8 cases. The radiological appearance after treatment was normal in 10 cases and abnormal in 17 cases. All patients received post-HPCT antifungal prophylaxis with itraconazole (12 cases), voriconazole (1) amphotericin (12) and fluconazole (2). After a median follow-up of 193 days (range 9 -2241), only 3 patients (2 allografts, 1 autograft) had a relapse of IFI, that caused their death in all cases (2, 3 and 9 months after HPCT). 1 of them had received TBI and 2 were receiving treatment for GvHD. Interestingly, these 3 patients had achieved complete pre-HPCT radiological clearance, 2 of them without surgery. Each patient was receiving a different form of prophylaxis. Overall, 7 patients are alive and disease-free. 10 patients died from disease progression and 10 from transplant-related toxicity, including IFI. In our experience, the risk of post-HPCT reactivation of a previous IFI is low (11%), so IFI should not be an absolute contraindication for HPCT. The combination of aggressive antifungal treatment (plus surgery when appropriate) with antifungal prophylaxis throughout HPCT, reduces the probability of reactivation. We could not identify any factor significantly improving outcome, although the use of more aggressive prophylaxis in patients likely to suffer GvHD seems necessary.
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Methicillin-resistant Gram-positive bacteremia in hemopoietic stem cell recipients: study of 390 cases D. Caldera, M. Varettoni, C. Baraté, P. Bernasconi, A.A. Colombo, E. Rumi, E. Giacobone, R. Daturi, M. Lazzarino, E.P. Alessandrino (Pavia, I) We analyzed the incidence of bacteremia during the aplastic post-transplantation phase, for 390 consecutive pts, who underwent HSCT in our Bone Marrow Ttransplantation Unit. The aims of the study were to evaluate the incidence of Gram+ bacteremia, the occurrence of methicillin-and glycopeptidesresistance (MR and GR), and its change over time. From January 1996 and December 2001, 390 pts entered the study; median age was 45 yrs (range 13-63), 219 were males and 171 females. The diagnoses were: ANLL (96 cases), ALL (25) (2), Enter. faecium (2). MR was documented in 60% of isolates: in 100% of St. Aureus, 66% of CNS and 38% of Streptococci. All Gram+ isolates were susceptible to vancomicine; susceptibility to teicoplanine was documented in 45/50 isolates (90%), while a complete resistance was showed in 5 CNS. In order to evaluate epidemiological changes during the considered period, we compared the isolates of 1996-1998 with those of 1999-2001: we observed a significant increase of the incidence of Gram+ infection, from 50% to 75% in the last three years; the MR and GR were stable over time. The low GR observed. may be due to the choice to avoid the Gram+ prophylaxis during CVC insertion and aplastic phase. Glycopeptides are actually the most effective antibiotics against MR-Gram+; ongoing surveillance of MR and GR is useful to adapt the empirical treatment and to stress the importance of non-pharmacological infection control practices.
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Efficacy of caspofungin in neutropenic and non-neutropenic patients A. Glasmacher, O. Cornely, K. Orlopp, G. Egerer, S. Blaschke, M. Siemann, S. Reuter, M. Florek, S. Kathofer, R. Schnitzler, H. Reinel, G. Just-Nuebling (Bonn, Cologne, Heidelberg, Goettingen, Kiel, Ulm, Dresden, Nuremberg, Frankfurt, D) Background: Caspofungin has shown efficacy in clinical trials in esophageal candidiasis, refractory invasive Aspergillus infections and candidemia. We here report the currently largest series of patients treated with caspofungin outside clinical trials. Methods: Centers in Germany that were known to treat patients with invasive fungal infections were asked to fill out questionnaires for all patients treated with caspofungin that describe the underlying disease, the indication for treatment, the diagnosis of the fungal infection as well as the toxicity and efficacy of caspofungin. No effort was made to influence the decision to use caspofungin. Results: 60 patients were evaluable at this deadline (median age 49 yrs, interquartile range 39-62). 37 suffered from a cute leukemia, lymphoma, myeloma or had had autologous stem cell transplants, nine had allogeneic stem cells transplants and 13 had other causes for immunosuppression. 23 patients were neutropenic. 25 patients received at least one non-cytostatic, immunosuppressive drug, 7 ciclosporine. Although there were rises in ALT, gGT and bilirubin from baseline to maximum values during caspofungin treatment, these values returned to baseline at the end of the caspofungin therapy. Bilirubin was higher in patients who received ciclosporin but it did not change during caspofungin treatment. 18 fungal infection were proven according to EORTC/MSG criteria, 27 probable and 15 possible. 24 patients had been treated with one, 21 patients with two or more antifungals before caspofungin. Nine patients received combination therapy. Overall, 31/51 evaluable patients achieved a complete or partial remission (61%, 95%CI 46-74%), 9 (18%) a clinical stabilization and 11 (22%) failed. Twelve (20%) patients died during caspofungin therapy. Response rates were similar in proven (11/17, 65%) and probable (12/22, 55%) infections, in neutropenic (15/19, 79%) and non-neutropenic patients (7/16, 44%) or in patients with (23/37, 62%) or without (7/13, 54%) antifungal pretreatment. Conclusions: This unselected survey of patients with invasive fungal infections treated outside clinical trials demonstrates low toxicity and good efficacy of caspofungin.
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Galactomannan antigenemia: three-year single center clinical experience N. Mordini, D. Mattei, R. Calvi, S. Tavera, M. Grasso, D. Ghirardo, L. Ferrua, E. Raviolo, C. Castellino, M. Pistone, P. Olivieri, A. Gallamini (Cuneo, I) During years 2000-2002 we performed sequential monitoring for the early detection of invasive aspergillosis (IA) in immunocompromised hosts with serum semiquantitative ELISA assay for Aspergillus spp galactomannann (Platelia ®), performed twice in a week, combined with weekly chest computer tomographic (CT) scan. We performed 1300 ELISA tests for 109 patients, accounting for 162 hematological treatments, as follows : acute leukemia (AL) induction/consolidation, high dose sequential therapy with peripheral blood autologous stem cell transplantation (auto PBSC) or autologous bone marrow transplantation (auto BMT), immunosuppressive treatment (IS) with antilymphocyte globulin for AA/MDS, fludarabine or 2-CDA based regimens for chronic lymphocytic leukemia (LLC) and Hairy Cell Leukemia, allogeneic stem cell transplantation (alloSCT). Diagnosis of IA (proven or probable) was done according to the EORTC/MSG criteria. Autologous procedures included 44 auto PBSC for 22 multiple myeloma (MM) and 22 non-Hodgkin lymphoma (LNH) patients, and 3 auto BMT for LLC patients. No evidence of IA was found in MM and CLL autografted patients. 4 probable IA occurred among LNH patients only in relapsed/resistant disease, 3 proven and 3 probable IA in 36 AL patients; 1 proven and 2 probable IA cases in 14 allo-SCT recipients, 1 proven IA out of 6 MDS/SA patient, and 1 proven and 1 probable IA cases out of 7 LLC. Considering a cut-off value of positive test > 1, the overall sensibilty of ELISA assay was 92%, and the specifity was 99%.We observed a clear correlation between the ELISA assay index and the clinical response to the antifungal therapy: in all the responding patients the antigenemia cleared up to the basal values and in the resistant the values were persistently higher than 1. We conclude that 1) The Elisa assay could enable an early diagnosis of IA, 2) patient diagnosed with MM and LNH treated with high dose sequential therapy program aren't at risk of IA if they are chemoresponsive, 3) LLC patients aged more than 60 years treated with fludarabine-based regimen seem to be at risk to develop IA, 4) AL patients and alloSCT recipients are at high risk of IA. We suggest that sequential monitoring with ELISA test during antifungal therapy identify very early resistant IA, and warrants a prompt modification of antifungal therapy.
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Klebsiella pneumoniae infections after stem cell transplantation -incidence, clinical manifestations, outcome and risk factors D. Engelhard, S. Straussman, C. Block, N. Strauss, S. Slavin, R. Or (Jerusalem, IL) 
